Inve India ▾

Windlas Biotech share price & results

Windlas Biotech Limited· Healthcare

Results to
Mar 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Dehradun pharma CDMO making tablets, capsules & injectables for India's top drugmakers and its own brands.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue238 ₹ crore+17.2% YoYQuarterly, as filedQuarter to Mar 2026Revenue from operations as filed.
Operating margin11.0 %−2.0 pts YoYOperating profit / revenueQuarter to Mar 2026For the quarter; a change is in percentage points.
Net profit16.0 ₹ crore0.0% YoYQuarterly, as filedQuarter to Mar 2026Profit after tax as filed.
Return on equity12.34 %−0.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Mar 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin4.09 %+2.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)18.82 %−1.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Mar 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Mar 2026

Guidance

What management said, and what became of it

1 of 2 judged targets kept · 7 open · verdicts reflect calls analysed to Q1 FY27.

Windlas Biotech Limited management guidance track record on Inve: 9 targets tracked across analysed earnings calls (1 achieved, 1 missed, 7 open).

TargetOriginal wordingSaidLatest callVerdict
Dividend Payout Ratiopolicy of 20% of profits
Call transcript, Q4 FY25 · 23 May 2025		Q4 FY25Q1 FY27:FY26 dividend of INR 13 cr declared. This represents a ~15.6% payout ratio, below the 20% policy target.
Call transcript, Q1 FY27 · 11 Aug 2026		Achieved*
Stockist Countgo to somewhere like 5,000, 6,000 stockists
Call transcript, Q4 FY25 · 23 May 2025		Q4 FY25Q1 FY27:No update provided on stockist count expansion for the second consecutive quarter.
Call transcript, Q1 FY27 · 11 Aug 2026		Ghosted
Plant 6 ReadinessWithin FY '26, it should be ready.
Call transcript, Q4 FY25 · 23 May 2025		Q4 FY25Q1 FY27:Reiterated on track for commercialization by end of H1 FY27, with validations and customer audits ongoing.
Call transcript, Q1 FY27 · 11 Aug 2026		On Track

Source: Inve Guidance Tracker for Windlas Biotech Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Windlas Biotech Limited's 9 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 6 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹877.4 −0.58% · −₹5.1

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −5.5% 1Y

₹0.7k₹0.8k₹0.9k₹1.0k₹1.1kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 7 Nov 2025Q3 FY26 — 11 Feb 2026Q4 FY26 — 22 May 2026Q1 FY27 — 11 Aug 2026

1Y: ₹928.85 on 24 Oct 2025 → ₹877.4. High ₹1,154.75 (7 Sept 2026), low ₹705.75 (16 Mar 2026).

Previous close
₹882.5
Market cap
₹1.8k Cr
52-week range
₹705.75 – ₹1,154.75
One year
−6.78%
Price to earnings (TTM to Mar 2026)
27.18×
Return on equity (TTM to Mar 2026)
12.34%

Overview

Symbol
NSE:WINDLAS
Exchange
NSE
Currency
INR

What Windlas Biotech Limited does

Based on the company's own presentations, annual report and earnings calls.

Windlas Biotech is a contract development and manufacturing organisation (CDMO) for generic pharmaceutical formulations, developing and manufacturing branded-generic tablets, capsules, oral liquids and injectables that partner pharma companies sell under their own brands. It also sells its own-brand generics directly to stockists and distributors (Trade Generics & Institutional) and exports formulations and health supplements to select international markets. Windlas owns the formulation IP for nearly all products it manufactures and runs its own R&D and dossier-development capability to support new product launches and regulatory filings for customers.

Segments

  • Generic Formulations CDMO
  • Trade Generics & Institutional
  • Exports
Manufacturing plants
5, all WHO-GMP compliant (Dehradun, Uttarakhand)
Installed capacity – tablets & capsules
8,522 Mn units/year
Installed capacity – pouches & sachets
54 Mn units/year
Installed capacity – liquid bottles
61 Mn units/year
Customers served
926
Brands catered to (CDMO)
5,644 across therapeutic areas
Founded 2001Headquarters Dehradun, UttarakhandEmployees 1,146 (FY2024-25) Company website

How the price took the results

close before → close after

Q1 FY27
+12.3%
11 Aug
Q4 FY26
+1.0%
22 May
Q3 FY26
−7.1%
11 Feb
Q2 FY26
−5.7%
7 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Windlas Biotech Limited

Free account: one company. Everything above stays public.

Write why you follow Windlas Biotech Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Windlas Biotech Limited

Guides on how to read this kind of business and the numbers that matter.